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In the present study, the question was addressed whether the feline placenta can synthesize prostaglandin F
2𝛼
(PGF
2𝛼
). The PGFS
protein was elevated, particularly at 2.5–3 weeks of pregnancy compared to 7-8 (𝑃 < 0.05) and 8.5–9 weeks (𝑃 < 0.001). Transcripts
for PGFS were significantly upregulated at 2.5–3 weeks of pregnancy and then gradually declined towards the end of gestation
(𝑃 < 0.001). Transcripts for PTGS2were only upregulated in placentas from queens close to term (𝑃 < 0.001) comparedwith earlier
phases. Staining of PTGS2 showed distinct positive signals in placentas obtained during the last week before labor, particularly in
the strongly invading trophoblast surrounding blood vessels, and also in decidual cells. Shortly after implantation, signals for PGFS
were localized in the trophoblast cells. Near term, PGFS stainingwas seenmainly in decidual cells. Both placental PGF
2𝛼
and plasma
PGFM were elevated towards the end of pregnancy (𝑃 < 0.001) compared with earlier weeks of pregnancy. The content of PGF
2𝛼
in extracted placenta mirrored the PGFM level in plasma of pregnant females. During late gestation there is a significant increase
in PGFM levels in maternal blood and of PGF
2𝛼
levels in placental tissue concomitant with an upregulation of placental PTGS2.
1. Introduction
The domestic cat (Felis catus) is seasonally polyestrous, with
ovulation usually provoked by coitus [1, 2]; however in as
much as 30–50% of the cycles, ovulation is spontaneous [3].
During the breeding season, which extends from February-
March until late summer in moderate latitudes [4], the cat
exhibits several estrous cycles. If ovulation is not followed by
pregnancy, the queen enters pseudopregnancy (a nonpreg-
nant luteal phase) that lasts only about one-half of a normal
gestation [5]. The length of the luteal phase in pregnant
queens, accompanied by elevated progesterone (P
4
) levels, is
assumed to be partially driven by luteotrophic and luteolytic
factors of placental origin [6]. In the dog, the uteroplacental
unit seems to serve as the major source for the prepartum
release of the luteolytic PGF
2𝛼
[7–9].
Even though the luteal phase in pseudopregnant cats is
much shorter than in the dog, one may speculate that the
feline CL possesses an intraluteal mechanism that triggers its
demise at the appropriate time.The life-span of the CL in the
pregnant cat is longer than in pseudopregnant queens; how-
ever, it needs to be precisely regulated to allow the onset
of parturition. Although PGF
2𝛼
seems to be a very potent
luteolysin, its role in regulating the CL of pregnancy in cats
is still uncertain. Shille and Stabenfeldt [10] showed that high
doses and repeated treatments with PGF
2𝛼
on days 11–15 after
mating had almost negligible effects on progesterone levels in
cats, which initially diminished but shortly afterwards recov-
ered completely following treatment. Similarly, PGF
2𝛼
given
on days 4 and 5 or 12 and 13 had no effect nor on circulating P
4
neither on CL size as monitored laparoscopically [11]. In
female cats on days 21–25 after mating, luteal function was
transiently depressed after treatment, but eventually the treat-
ment did not alter the length of the luteal phase compared
with untreated cats [10]. However, exogenously administered
PGF
2𝛼
or its analogue has a luteolytic effect on fully developed
CLs after day 33 [12] or day 40 of gestation [13].
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Recently, the PGF
2𝛼
inactivemetabolite 13,14-dihydro-15-
keto prostaglandin F
2𝛼
(PGFM), measured in the feces, was
shown to be a precise pregnancy indicator in several felid
species, including the domestic cat, during the last trimester
of gestation [14]. The uteroplacental complex was proposed
to be a source of PGF
2𝛼
in cats [14]. We hypothesize that
the placenta of the domestic cat synthesizes PGF
2𝛼
in a time-
dependent manner. To address this hypothesis, we examined
in the feline placenta (1) the cellular localization of PGFS
(AKR1C3), (2) the PGFS protein and mRNA content, (3) the
cellular localization of PTGS2 and its mRNA expression, and
(4) the tissue level of PGF
2𝛼
at different gestational stages.
Moreover, in maternal blood plasma the PGF
2𝛼
metabolite
PGFM was measured throughout gestation.
2. Materials and Methods
2.1. Animals, Tissue Sampling, and Preservation. All proce-
dures were approved by the Local Animal Care andUseCom-
mittee in Olsztyn, Poland (61/2010/DTN). Thirty domestic,
healthy cats, aged 1–6 years were brought into a local veteri-
nary clinic for neutering. Ovariohysterectomy was done with
the owner’s request and consent. Four groups were created
with queens ovariohysterectomized according to the follow-
ing schedule.
(1) Postimplantation, early gestation, days 18–21 (2.5–3
weeks), 𝑛 = 8.
(2) Mid gestation, days 28–35 (4-5 weeks), 𝑛 = 8.
(3) Late gestation, days 49–56 (7-8 weeks), 𝑛 = 7.
(4) Before parturition, days 60–64 (8.5–9 weeks), 𝑛 = 6.
Additionally, samples were collected from one cat during
hysterectomy around day 14 of gestation (peri-implantation
period).
The day of mating, known in 18 females, was recorded as
day 0. Confirmation of gestational age, whenever the day of
mating was unknown, was done according to the measure-
ments of the crown-rump length in fetuses and uterine
ampullae diameters or lengths [15, 16]. In addition, mea-
surements of the progesterone (P
4
) values reported in the
literature [17] and confirmed in our last report [18] were per-
formed. Blood was drawn preanesthesia. Blood samples were
collected from the cephalic vein into EDTA-containing tubes
(TycoHealthcareGroupLP,Mansfield,USA) and transported
to the laboratory at 4∘C. Plasma obtained after blood centrifu-
gation (3500×g, 10min) was frozen at −20∘C until P
4
and
PGFM measurements . Direct enzyme immunoassay (EIA)
was done for hormonal analysis.
Tissues were washed immediately after surgery with
sterile saline to remove blood contamination then were
placed into fresh sterile saline at 4∘C and transported to the
laboratory within 1 h. Uterine horns were slit longitudinally
and pieces of uterus with attached placenta were prepared,
washed in fresh saline to remove blood, preserved overnight
at 4∘Cwith RNAlater (Ambion Biotechnologie GmbH,Wies-
baden, Germany), and then stored at −80∘C until total-RNA
extraction. Another fragment of the same placenta was fixed
in buffered 4% formaldehyde for 24 h, dehydrated, and wax-
embedded. Sections (2-3 𝜇m thick) were used to determine
PGFS and PTGS2 protein localization by immunohistochem-
istry. Transcripts of PGFS and PTGS2 were determined using
Real-Time PCR, while the content of PGFS protein was
determined by western blot analysis.
2.2. RNA Isolation, Reverse Transcription, and Real-Time
PCR. Total RNA was isolated from feline placenta using
TRIZOL-reagent according to the manufacturer’s instruc-
tions (Sigma Aldrich, Warszawa, Poland). The RNA content
was measured with a Nanodrop 1000 Spectrophotometer
(Thermo,USA). Prior to reverse transcription, genomicDNA
contaminationwas removed by treatmentwithDNase (Sigma
Aldrich, Warszawa, Poland). Reverse transcription was per-
formed using the ImProm-II Reverse Transcription System
(Promega, Warszawa, Poland) according to the manufac-
turer’s protocol. In brief, an experimental reaction contained
1 𝜇g of RNA in 12 𝜇L of reaction mix, 4 𝜇L of reaction buffer,
2.5 𝜇L of MgCl
2
(final concentration 3mM), 1 𝜇L of dNTP
Mix (final concentration 0.5mM each dNTP), and 1 𝜇L of
ImProm-II Reverse Transcriptase. The final volume of the
RT reaction mix was 20.5𝜇L. The tubes were placed in a
thermocycler (Bio-Rad Laboratories, Hercules, CA, USA)
equilibrated at 25∘C and incubated for 5min. For the next
step, tubes were incubated in a thermocycler for 1 h at 42∘C.
For Reverse Transcriptase inactivation, the temperature was
increased to 70∘C for 15min. Sampleswere kept at−20∘Cuntil
analyzed by Real-Time PCR.
The levels of mRNA expression of target genes were
examined by Real-Time PCRusing specific primers for PGFS,
PTGS2, and cyclophilin A (Cyc). Among several housekeeping
genes that have been already examined for their stability and
efficiency [Jursza, Siemieniuch, 2013, unpublished], Cyc was
used as a housekeeping gene. All primers were purchased
from Sigma Aldrich (Warszawa, Poland) and were tested
in our previous report [18, 19]. The sequences were as
follows: PGFS forward: 5󸀠-TCAACCAGAGCAAACTGC-
TG-3󸀠, PGFS reverse: 5󸀠-CATTCCTTCCCTGAGTTGGA-3󸀠
(GenBank accession number HM490147); PTGS2 forward:
5󸀠-AACAGGAGCATCCAGAATGG-3󸀠; PTGS2 reverse: 5󸀠-
GCAGCTCTGGGTCAAACTTC-3󸀠 (GenBank accession
number EF036473); Cyc forward: 5󸀠-CCTTCTGTAGCT-
CGGGTGAG-3󸀠; Cyc reverse: 5󸀠-CTTGGAGGGGAGGTA-
AGGAG-3󸀠 (GenBank accession number AY029366).
The Real-Time PCR reactions were carried out in an
automated fluorometer ABI PRISM7300 SequenceDetection
System (Applied Biosystems, Darmstadt, Germany) using
SYBR Green Master Mix (Applied Biosystems, Applera,
Warsaw, Poland). The PCR reactions were performed in 96-
well plates. The total reaction volume was 20 𝜇L containing
1 𝜇L cDNA (200 ng), 500 nM each of forward and reverse
primers, and 10 𝜇L SYBR Green PCR Master Mix. Real-time
PCR was carried out as follows: initial denaturation (10min
at 95∘C), followed by 40 cycles of denaturation (15 s at 95∘C),
and annealing (1min at 60∘C). After each PCR reaction,
melting curves were obtained by stepwise increases in tem-
perature from 60 to 95∘C to ensure single product amplifi-
cation. The presence of the product was also confirmed by
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electrophoresis on 2% agarose gel. Relative quantificationwas
performed by normalizing the signals of target genes with the
Cyc signal using the Miner method for quantifying qRT-PCR
results, using calculations based on the kinetics of individual
PCR reactions [20].
2.3. Protein Preparation and Western Blotting. Tissue homo-
genates were prepared with NET-2 lysis buffer containing
50mM Tris-HCl, pH = 7.4, 300mM NaCl, 0.05% NP-40,
and protease inhibitor cocktail (10 𝜇L/mL). Tissues were
centrifuged at 10,000 g for 10min at 4∘C; then proteins in the
supernatant were disrupted using a sonicator (75W for 15 s).
The concentrations of protein were determined by the Brad-
ford assay with a spectrophotometer (SmartSpec Plus, Bio-
Rad). Proteins were solubilized in sample buffer (25mmol/L
Tris-Cl, pH = 6.8, 1% SDS, 5% 𝛽-mercaptoethanol, 10%
glycerol, and 0.01%bromophenol blue), placed onto 12%SDS-
polyacrylamide gel, and separated at 120V. Afterwards, pro-
teins were transferred onto methanol-activated PVDF mem-
branes for 1 h at 100V. To block nonspecific binding, mem-
branes were incubated for 1 h in nonfat dry milk, 5% in PBS
with 0.25% Tween 20. Membranes were incubated overnight
at 4∘C with canine-specific guinea pig polyclonal affinity
purified anti-PGFS (AKR1C3) custom-made antibody (Euro-
gentec S.A., Seraing, Belgium), at a dilution of 1 : 400, as
described by Gram et al. [8]. After this, membranes were
washed three times for 10min in PBS with Tween-20 at 20∘C.
Next, membranes were incubated with horseradish peroxi-
dase (HRP)-conjugated secondary antibody (Sigma, dilution
1 : 15.000) for 1 h at room temperature (RT).
As a loading control, PVDF were reblotted with anti-
𝛽-actin mouse monoclonal antibody (sc-69879, Santa Cruz
Biotechnology, Rockford, IL, USA, dilution 1 : 1000). Results
were visualized using the SuperSignalWest FemtoMaximum
Sensitivity Substrate according to themanufacturer’s protocol
(Thermo Scientific, USA) and the ChemiDoc XRS+ System
and Image Lab (BioRad). The optical density of bands was
determined using ImageJ software.
2.4. Immunohistochemistry. Formalin-fixed, paraffin-embed-
ded tissues were cut with amicrotome (2-3𝜇m) andmounted
on SuperFrost Plusmicroscope slides (Menzel-Gla¨ser, Braun-
schweig, Germany). The experimental protocol was as pre-
viously described for feline placenta [18]. Briefly, slides were
deparaffinized and rehydrated in a graded ethanol series
and then incubated in citrate buffer (10 nM, pH 6.0) for
15min under microwave irradiation at 560W for antigen
retrieval. Then, sections were incubated in 0.3% H
2
O
2
in
methanol for 30min to quench endogenous peroxidase and
thenwashed in IHC-buffer/0.3%TritonXpH7.2–7.4 (0.8mM
Na
2
HPO
4
, 1.47mM KH
2
PO
4
, 2.68mM KCl, and 1.37mM
NaCl). Blocking of nonspecific binding sites was performed
in 10% goat or rabbit serum. The following primary anti-
bodies were used: canine-specific guinea pig polyclonal
affinity purified anti-PGFS (AKR1C3) antibody (dilution
1 : 400) (Eurogentec S.A., Seraing, Belgium), the same as for
western blot and as recently applied for canine uteroplacen-
tal tissue [8], and affinity purified goat anti-rat polyclonal
antibody raised against the N-terminus of COX2 (Santa
Cruz Biotechnology, Inc., CA, USA). The negative controls
were as follows: slides without the primary antibody and
slides incubated with nonimmunized guinea pig or goat
serum, respectively, at the same dilution and protein con-
centration as primary antibodies. Sections were incubated
overnight at 4∘C. After washing with IHC-buffer, slides were
incubated for 30min at RT with either biotinylated goat
IgG (secondary antibody, dilution 1 : 100) against guinea pig
immunoglobulin (Vector Laboratories, Burlingame, US) or
biotinylated rabbit IgG antibody (dilution 1 : 100) against
goat immunoglobulin (Vectastain ABC Kit, Vector Labora-
tories). For enhancing signals, sections were incubated with
the avidin-biotin-peroxidase complex (Vectastain ABC kit,
Vector Laboratories) for 30min at RT. After washing with
IHC-buffer, sections were allowed to react with the substrate
diamino-benzidine (DAB; DakoCytomation, Glostrup, Den-
mark) according to the manufacturer’s instructions. Slides
were counterstainedwith hematoxylin, rinsed under running
tapwater for 5min, dehydrated in a graded ethanol series, and
mounted in mounting medium DPX (Panreac Quimica Sau,
Barcelona, Spain).
2.5. Placental PGF
2𝛼
Extraction. For PGF
2𝛼
extraction, the
protocol elaborated by Tsang et al. [21] and tested for feline
placental progesterone extraction by Siemieniuch et al. [18]
was applied, with some minor modifications. Briefly, placen-
tal fragments weighing 200–220mg were stored at −80∘C.
After thawing, each tissue sample was homogenized in a glass
vial using a tissue disruptor with 400𝜇L of a Tris buffered
saline containing proteins and sodium azide as preservative
and acidified by addition of 45𝜇L 1NHCl. After adding 3mL
of ethyl ether to the samples, they were vortexed for 10min
and incubated at −20∘C for 4 h. Afterwards, the supernatant
was collected and evaporated to dryness under a stream of
nitrogen at 40∘C. Finally, 400 𝜇L of the Tris buffered saline
was added, mixed, and allowed to sit for 15min at 20∘C. The
sampleswere stored at−20∘Cuntil the immunoassaywas run.
2.6. Prostaglandin F
2𝛼
(PGF
2𝛼
), 13,14-Dihydro-15-keto Pros-
taglandin F
2𝛼
(PGFM), and Progesterone (P
4
) Determination.
For PGF
2𝛼
and PGFMmeasurements, the commercial PGF
2𝛼
high sensitivity EIA kit (ENZO Life Sciences Inc., Farm-
ingdale, NY, USA) and 13,14-dihydro-15-keto Prostaglandin
F
2𝛼
EIA kit (Cayman Chemical Company, Ann Arbor, MI,
USA)were used, respectively, and run according to themanu-
facturers’ instructions.
The sensitivity of the PGF
2𝛼
assay was 0.98 pg/mL. This
assay is based on the competition between free PGF
2𝛼
and a
PGF
2𝛼
tracer for a limited number of PGF
2𝛼
-specific sheep
antiserum binding sites. The cross-reactivity for various
prostaglandins and their metabolites was as follows: PGF
2𝛼
100%, PGF
1𝛼
11.82%, PGD
2
3.62%, 6-keto-PGF
1𝛼
1.38%, PGI
2
1.25%, and PGE
2
0.77%. The inter- and intraassay precision
variation was 6.8% and 10.1%, respectively.
The sensitivity of the PGFM assay was 15 pg/mL. This
assay is based on the competition between free 13,14-dihydro-
15-keto PGF
2𝛼
and a 13,14-dihydro-15-keto Prostaglandin F
2𝛼
4 Mediators of Inflammation
(a) (b) (c)
(d) (e) (f)
Figure 1: PGFS (AKR1C3) protein localization in the uteroplacental unit. Immunohistochemical (IHC) localization of PGFS in the week 2
of pregnant uterus (a) and placenta at week 3 (b), week 6 (c), and week 9 of gestation ((d), (e)). (a) In the feline uterus some weak PGFS
signals are localized in the glandular epithelium (open arrowheads); ((b), (c)) in the placental labyrinth, PGFS expression is localized in
the fetal trophoblast cells (solid arrowheads). ((d), (e)) In the fully developed placenta, towards the end of pregnancy, signals are weaker in
trophoblast cells and are mostly localized in maternal decidual cells (open arrowheads). (f) Isotype control.
tracer for a limited number of 13,14-dihydro-15-keto PGF
2𝛼
-
specific rabbit antiserum binding sites. The cross-reactivity
for various prostaglandins and their metabolites was as fol-
lows: 13,14-dihydro-15-keto PGF
2𝛼
100%, 13,14-dihydro-15-
keto PGE
2
2.7%, and 15-keto PGF
2𝛼
1.8%. The inter- and
intraassay precision variation was 8.3% and 14.5%, respec-
tively.
For P
4
measurement, a commercial Progesterone ELISA
kit (ENZOLife Science) was used and run in accordance with
the manufacturer’s instructions. This kit uses a polyclonal
antibody to P
4
to bind, in a competitive manner, P
4
in a
sample or P
4
with a covalently attached alkaline phosphatase
molecule. The sensitivity of this P
4
assay was 8.57 pg/mL.
The cross-reactivity for a number of related steroids was as
follows: P
4
100%, 5𝛼-Pregnane-3,20-dione 100%, 10-OH-
progesterone 3.46%, corticosterone 0.77%, and deoxycorti-
costerone 0.28%.The inter- and intraassay precision variation
was 8.1% and 9.5%, respectively.
2.7. Statistics. To test the effect of different stages of preg-
nancy on mRNA levels and on PGFM or PGF
2𝛼
concen-
trations, the Kruskal-Wallis Test (a nonparametric ANOVA)
was used followed by the Newman-Keuls Multiple Compar-
ison Test using the statistical software program GraphPad6
(GraphPad PRISM v 6.0; GraphPad Software Inc., San Diego,
CA, USA). PGFM concentrations in plasma or PGF
2𝛼
con-
centrations in the placenta are shown as a mean ± standard
deviation. Significance was defined as values of 𝑃 < 0.05.
3. Results
3.1. Placental Expression of PGFS throughout Pregnancy. In
the uterus at the peri-implantation period (2nd week of
pregnancy), no or very weak signals were observed in the
glandular epithelium (Figure 1(a)). After implantation (3rd
week of pregnancy), and in fully developed placenta at the
7th week of gestation, strong placental signals were localized
in fetal trophoblast cells (Figures 1(b) and 1(c), resp.). Towards
the end of pregnancy (9th week) signals in trophoblast cells
were much weaker, and were localized in the maternal decid-
ual cells (Figures 1(d) and 1(e)). Negative controls showed no
staining (Figure 1(f)).
In the western blot analysis, the PGFS was detected as a
protein with a molecular size of approximately 34–36 kDa.
The expression of PGFS protein was strongly affected by
gestational age (Figure 2).ThePGFS proteinwas upregulated,
particularly in the first period studied, at 2.5–3 weeks of
pregnancy, compared to samples collected at 7-8 gestational
weeks (𝑃 < 0.05) or 8.5–9 weeks (𝑃 < 0.001).
The expression of transcripts for placental PGFS as
determined by Real-Time PCR was strongly time-dependent
(Figure 3(a)). The PGFS mRNA transcripts were mirrored
by PGFS protein expression in western blot analysis. The
PGFS mRNA was significantly upregulated at the 3rd week
of pregnancy and then gradually declined towards the end of
gestation (𝑃 < 0.001).
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Figure 2: PGFS (AKR1C3) protein expression. Time-dependent
expression of PGFS protein in the feline placenta. Tissue
homogenates (30 𝜇g) were used in western blot analysis (𝑛 = 16).
Representative immunoblots are shown. Lower panel represents
densitometric values for PGFS normalized against B-actin (mean ±
S.D.).
3.2. Placental Expression of PTGS2 throughout Pregnancy.
The IHC analysis revealed abundant positive signals in 9th
week feline placenta. Strong staining was observed in the
invading fetal trophoblast cells surrounding maternal blood
vessels (Figure 4(a)). Similarly, strongly positive signals were
observed in the maternal decidual cells in the 9th week of
pregnancy (Figure 4(b)). No signals were noted in the neg-
ative controls (Figure 4(c)). Only weak signals were observed
for placental PTGS2 protein expression during earlier
stages of pregnancy.
The expression of transcripts for placental PTGS2,
as determined by Real-Time PCR, was time-dependent
(Figure 3(b)). PTGS2 mRNA expression was basal during
early and midgestation, started to increase during late gesta-
tion, and was significantly upregulated during the prepartal
phase (𝑃 < 0.001).
3.3. Placental Prostaglandin F
2𝛼
(PGF
2𝛼
) and Blood Plasma
13,14-Dihydro-15-keto Prostaglandin F
2𝛼
(PGFM) Content.
The levels of PGF
2𝛼
extracted from placentas mirrored the
PGFM levels measured in peripheral blood plasma of preg-
nant females throughout gestation, as shown in Figures 5(a)
and 5(b), respectively. Both placental PGF
2𝛼
and plasma
PGFMwere elevated towards the end of pregnancy compared
to the values obtained at the 3rd week of pregnancy (𝑃 <
0.001).
4. Discussion
To examine the role of prostaglandins in the feline placenta
near the end of pregnancy, the transcripts for PTGS2 and
its cellular localization were analyzed. PTGS2, the crucial
enzyme in generating prostaglandin, catalyzes the conversion
of arachidonic acid into endoperoxide PGH
2
, which is a
precursor of all prostaglandins [22, 23]. In the present study,
transcripts for PTGS2 were upregulated in placentas solely
from queens in the last week before termination of the preg-
nancy.These findings are in agreement with a previous report
of an acute increase of PTGS2 transcripts in the placenta in
the dog during prepartum luteolysis [7]. In the present study,
the protein localization of PTGS2 was found in both fetal
trophoblast and maternal decidual cells. In contrast, both
protein and transcripts for PGFS (AKR1C3) were strongly
upregulated soon after implantation, which takes place on
days 12–14 after ovulation in the cat [24]. Transcripts for PGFS
and PGFS protein were rather low in the placenta near the
end of pregnancy. These findings are in agreement with a
report of decreased PGFS transcripts in preparturient dogs,
which led to the conclusion that PGFS (AKR1C3) might be
not responsible for the sharp PGF
2𝛼
elevation just before term
in the bitch [7].
One of the questions addressed in this study was whether
PGFS (AKR1C3), that was shown to promote the direct
conversion of PGH
2
to PGF
2𝛼
[8], is responsible for placental
elevation of PGF
2𝛼
. In the dog, PGFS (AKR1C3) staining
was predominantly localized in the fetal trophoblast cells in
the fetomaternal contact zone, justifying the assumption that
PGFS may play a role in decidualization and placentation;
moreover, PGFS expressionwas low prior to implantation but
distinctly increased thereafter [8]. The cellular localization
of PGFS in the feline placenta from 3 weeks of gestation
is similar to that observed in the dog. Therefore, PGFS is
implicated in the processes of fetal membrane development
and placentation.Thediscrepancy observed between elevated
PGF
2𝛼
concentration in the placenta and downregulation of
PGFS (AKR1C3) protein and mRNA levels may be explained
by the number of enzymes involved in generation of the wide
variety of prostaglandins. PGF
2𝛼
is one of the few primary
prostaglandins derived enzymatically from the endoperoxide
PGH
2
. It can be directly synthesized from PGH
2
by PGF
2𝛼
synthase (PGFS), like AKR1C3 presented herein. However,
other pathways of PGF
2𝛼
synthesis, including enzymes
belonging to the aldo-ketoreductases family, for example,
AKR1B1 or AKR1B5, are possible. The canine PGFS cDNA
sequence has been cloned [25] and classified as an AKR1C3
and is the only canine-specific PGFS isoform known so far
[8]. The feline PGFS cDNA sequencing was based on a dog
cDNA sequence and showed 87% homology with the canine
PGFS [19]. Furthermore, PGF
2𝛼
may originate from conver-
sion of several other prostaglandins, including catalysis of
PGE
2
to PGF
2𝛼
by 9-keto-reductase (9KPGR), or perhaps
even at relatively low expression levels AKR1C3 is still not
rate-limiting for PGF
2𝛼
synthesis.
Recently, elevated concentrations of a stable PGF
2𝛼
metabolite (PGFM) were found in the feces of several felid
species in the last trimester of pregnancy [14]. In the present
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Figure 3: PGFS (AKR1C3) and PTGS2 mRNA expression. Time-dependent expression of feline PGFS (a) and PTGS2 (b) as determined by
Real-Time PCR. Asterisks indicate statistical differences between expression levels during the course of pregnancy (∗𝑃 < 0.05, ∗∗𝑃 < 0.001).
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Figure 4: PTGS2 protein localization in the placenta. Immunohistochemical localization of PTGS2 in feline placenta from the 9th week
of pregnancy. Positive signals are shown in the strongly invading trophoblast surrounding blood vessels (solid arrowheads) (a) and also in
maternal decidual cells (open arrowheads) (b). (c) Isotype control.
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Figure 5: Placental PGF
2𝛼
and serum PGFM values. Time-dependent content of PGF
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in placenta (a) and PGFM in blood plasma (b) as
determined by immunoassays. Asterisks indicate statistical differences between prostaglandin levels during the course of pregnancy (∗𝑃 <
0.05, ∗∗𝑃 < 0.001, and ∗∗∗𝑃 < 0.0001).
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study, the PGFM level, measured in feline plasma blood
collected just before ovariohysterectomy, was low during the
first and second trimesters of pregnancy and then started to
increase for the last 3 weeks of gestation. Certainly, PGFM
in the maternal plasma may not originate exclusively from
the placenta. Nevertheless, to examine whether the placenta
might support synthesis of PGF
2𝛼
, placental tissues from
different gestational weeks were extracted to obtain PGF
2𝛼
.
The PGFM blood plasma level was mirrored by the placental
PGF
2𝛼
concentration. The lowest amount of PGF
2𝛼
was
observed in tissue collected soon after implantation, indicat-
ing there is no likely biological role at this time. It explains
why in the earlier studies byWildt and coworkers [11] or Shille
and Stabenfeldt [10] PGF
2𝛼
failed to influence P
4
production
or reduce CL size. The first rise in concentration was seen at
the beginning of the second trimester, but the most distinct
increase coincided with the last week of gestation. The very
similar pattern of placental PGF
2𝛼
and its stable metabolite
in feline blood plasma may suggest the placental origin of
PGFM. However, this finding does not rule out an intraluteal
and/or uterine source of PGF
2𝛼
during pregnancy, especially
since components of the underlying synthetic pathways
were already found in the domestic cat CL (Zschockelt and
Siemieniuch 2013, unpublished). This is in contrast with the
canine CL, in which intraluteal prostaglandin synthesis is
associatedwith luteal formation but not with luteal regression
or luteolysis [8, 26, 27]. The strong prepartum increase in
circulating PGF
2𝛼
observed in the dog seems to be originated
from the uteroplacental compartment, where strongly upreg-
ulated expression of the prostaglandin system was reported
[7] and was evidenced by the increased output of PGF
2𝛼
from the canine placenta at the time of parturition [9].
Furthermore, the prepartum increase in peripheral PGF
2𝛼
in
the dog is accompanied by a steep P
4
decline, implicating
its role during luteolysis and/or fetal expulsion [28, 29].
These results partially agree with our present observations
concerning elevated PGFM levels in maternal blood in the
domestic cat and are consistent with the previous report from
our laboratory presenting a considerable decline of P
4
in both
maternal plasma and placental tissue in the last week of feline
pregnancy [18]. The latter observation, however, concerning
the P
4
levels does not relate to the immediate prepartum
time period but describes the strongly diminished P
4
levels
during the last gestational week [18]. At least, the luteolytic
role of PGF
2𝛼
in the second half of feline gestation is generally
accepted, since PGF
2𝛼
or its analogues given to females
with fully developed CLs induces luteolysis and consequent
abortion after day 33 [12] or day 40 of gestation [13].
In conclusion, the data presented here confirms that the
placenta of the domestic cat is capable of synthesizing PGF
2𝛼
in a time-dependent manner. Besides the fact that AKR1C3 is
not a rate limiting enzyme even at relatively low expression
levels, it may still be determinant for PGF
2𝛼
synthesis in the
feline placenta. However, other enzymes and other synthetic
pathways must also be taken into account. The peak of both
placental PGF
2𝛼
and maternal plasma PGFM coincides with
the beginning of the last week of pregnancy in cats, compared
to dogs, in which peak plasma PGFM is observed 24–48 h
before term. Other pathways involved in PGF
2𝛼
synthesis
in the cat placenta are possible and need to be elucidated.
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